American Journal of Psychiatry · 1999 · 120 citations · 5 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyLipid DisordersLipid-lowering TherapySchizophrenia PharmacotherapyTriglyceride MetabolismAtypical Antipsychotic TreatmentClozapine PharmacologyLipid Profile AnalysisLipid Profile ChangesLipid Profile ScreeningMedical Records ReviewPlasma Cholesterol Levels
OBJECTIVE: This study was conducted to determine serum lipid level changes in patients who received clozapine or haloperidol. METHOD: Medical records of 222 inpatients treated with clozapine or haloperidol were reviewed. Age, weight, gender, daily antipsychotic dose, total cholesterol level, serum triglyceride level, and concurrent medications were recorded. RESULTS: Clozapine-treated men had significantly higher follow-up serum triglyceride concentrations over baseline than did haloperidol-treated men. Female patients experienced serum triglyceride level elevations regardless of antipsychotic treatment. Changes in total cholesterol levels were not significantly different between treatment groups. CONCLUSIONS: An increase in serum triglyceride levels occurred in clozapine-treated patients; screening for serum triglyceride elevations may be warranted before treatment with clozapine.
5
Clozapine for the Treatment-Resistant Schizophrenic
John M. Kane · Archives of General Psychiatry · 1988 · 4.1K citations
Medicine, Pharmacology, Psychiatry +16
Agranulocytosis: incidence and risk factors.
PubMed · 1994 · 238 citations
Medicine, Pharmacology, Psychiatry +16
Daniel Umbricht, Simcha Pollack, J M Kane · PubMed · 1994 · 180 citations
Suzana Roitman, Yaffa Vered, Roberto Mester et al. · PubMed · 1998 · 97 citations
Medicine, Pharmacology, Psychiatry +14